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Abstract
Background: Mitochondrial myopathy severely affects skeletal muscle structure and function resulting in defective
oxidative phosphorylation. However, the major pathomechanisms and therewith effective treatment approaches
remain elusive. Therefore, the aim of the present study was to investigate disease-related impairments in skeletal
muscle properties in patients with mitochondrial myopathy. Accordingly, skeletal muscle biopsies were obtained from
six patients with moleculargenetically diagnosed mitochondrial myopathy (one male and five females, 53 ± 9 years)
and eight age- and gender-matched healthy controls (two males and six females, 58 ± 14 years) to determine
mitochondrial respiratory capacity of complex I-V, mitochondrial volume density and fiber type distribution.
Results: Mitochondrial volume density (4.0 ± 0.5 vs. 5.1 ± 0.8 %) as well as respiratory capacity of complex I-V
were lower (P < 0.05) in mitochondrial myopathy and associated with a higher (P < 0.001) proportion of type II
fibers (65.2 ± 3.6 vs. 44.3 ± 5.9 %). Additionally, mitochondrial volume density and maximal oxidative phosphorylation
capacity correlated positively (P < 0.05) to peak oxygen uptake.
Conclusion: Mitochondrial myopathy leads to impaired mitochondrial quantity and quality and a shift towards a more
glycolytic skeletal muscle phenotype.
Keywords: Bioenergetics, Fat oxidation, Mitochondria, Mitochondrial cytopathy, Neuromuscular disease, Skeletal
muscle phenotype
Background
Despite progress in understanding the biochemistry and
genetics of mitochondrial myopathy, many of the patho-
physiological mechanisms remain unclear [1]. Validated
therapeutic options as well as simple and effective diag-
nostic tools are lacking [1–5]. So far, it has barely been
investigated how muscle metabolism and morphology
may be affected by mitochondrial dysfunction. Fiber type
abnormalities including varying distribution of type I
and II fibers as well as general or selective atrophy have
been reported in patients with various mitochondrial
respiratory chain dysfunctions [6–8] but not in adults
with mitochondrial myopathy. In a rat model of mito-
chondrial myopathy [9] a transformation from type I to
type II fibers was observed in response to a primary
defect of the mitochondrial respiratory chain.
In addition, patients with mitochondrial myopathy
have been characterised by lower peak oxygen uptake
(V̇O2peak) and work capacity (Ppeak) when performing
cycling exercise [10–12]. This limited oxidative cap-
acity in mitochondrial myopathy patients is most
likely related to a limited O2 extraction with reduced
arterio-venous O2 difference in exercising muscles
[10–13]. The limited O2 extraction, in turn, might be
explained by an impaired oxidative capacity of the
mitochondria itself and/or a reduction in their num-
ber [14]. Exercise intolerance can be a prominent
clinical manifestation of mitochondrial myopathy,
leading to relatively low levels of exertion, fast
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fatigablity and a sedentary lifestyle [15, 16]. A seden-
tary lifestyle may further restrict the capacitiy of
skeletal muscle for oxidative phosphorylation by a
decrease in levels of functional mitochondria [17].
Hence, it remains difficult to distinguish to what
extent exercise intolerance is related to impaired
mitochondrial oxidative capacity or associated with
physical deconditioning. Assessments of muscle oxida-
tive capacity and potential alterations with mitochon-
drial myopathy have previously only been conducted
in single cases or small case series [11]. Thereby, de-
fects of the mitochondrial respiratory chain have been
identified polarographically or by enzymatic assays
[18, 19], usually involving complex I or III in adults
and complex IV in children [8, 20]. Poloarographic
measurements have been mainly conducted in com-
plex combinations and not independently for each
complex [21]. Moreover, these global assessments of
mitochondrial function were conducted in muscle
homogenates or isolated fibers [19]. Mitochondrial
isolation and homogenation procedures, however, may
disrupt the functional network and could thereby
alter innate mitochondrial characteristics [22]. There-
fore, in vitro measurements of O2 consumption in
permeabilised myofibers preserving innate mitochon-
drial function present a more promising approach to
determine mitochondrial characteristics [22]. Deter-
mination of the respiratory capacity of each individual
complex could lead to a better understanding of
mitochondrial function and identification of potential
mitochondrial-myopathy-related pathomechanisms. So
far, the absence of a consistent clinical phenotype has
limited the viability of clinical identification and clas-
sification criteria of mitochondrial myopathy [3, 21,
23]. However, detailed elucidation of potential patho-
mechanisms would be important not only for the
diagnosis of mitochondrial myopathy but also for
developing rational treatment options for mitochon-
drial myopathy.
Consequently, the primary aim of the present study
was to determine mitochondrial volume density and
respiratory capacity of each individual complex in
permeabilised muscle fibers of mitochondrial myopathy
patients by implementing high-resolution respirometry.
In our set of patients with moleculargenetically verified
mitochondrial myopathy and concomitant exercise in-
tolerance, we hypothesised that mitochondrial volume
density and respiratory capacity of each single complex
I-V would be decreased compared to age- and gender-
matched healthy controls. Furthermore, we aimed to test
whether high-resolution respirometry measurements
would represent a diagnostic tool leading to enhanced
diagnostic and classification criteria of mitochondrial
myopathy.
Methods
Aim, design and setting
The main aim of the study was to determine mitochon-
drial volume density and respiratory capacity of each
individual complex in permeabilised muscle fibers of
mitochondrial myopathy patients and age- and gender-
matched healthy controls by the application of high-
resolution respirometry measurements. The second aim
was to determine if human mitochondrial myopathy
with shift towards type II fibers. Additionally, we evalu-
ated if the applied mitochondrial respirometric measure-
ments would represent a diagnostic tool leading to
enhanced diagnostic and classification criteria of mito-
chondrial myopathy.
Participants
Six patients with mitochondrial myopathy, and eight
age-and gender-matched healthy controls, participated
in this study (Table 1). Patients were selected from a
patient base followed at the Center of Neuromuscular
Disorders Zurich (Department of Neurology, University
Hospital Zurich, Switzerland) and healthy controls were
matched by gender, age and by physical activity patterns
(assessed by interrogation). In all patients, clinical and
biopsy findings and/or molecular genetic analysis of
muscle mitochondrial DNA were in accordance with the
diagnosis of mitochondrial myopathy. Apart from
Table 1 Physiological characteristics of patients with
mitochondrial myopathy (n = 6) and healthy controls (n = 8)
Patients Controls P-value
Age (yr) 53 ± 9 58 ± 14 0.437
Body mass (kg) 75 ± 18 67 ± 12 0.376
Height (cm) 162 ± 7 167 ± 7 0.238
BMC (kg) 2.3 ± 0.18 2.4 ± 0.4 0.867
Fat mass (kg) 23.1 ± 16.3 14.2 ± 11.6 0.255
Lean mass (kg) 38.4 ± 13.3 41.4 ± 13.9 0.683
Lean mass legs (kg) 19.3 ± 11.1 19.0 ± 8.8 0.951
Total body fat (%) 39 ± 13 31 ± 6 0.153
Relative V̇O2peak (mL min
−1 kg−1) 19.8 ± 6.8a 32.6 ± 7.3 <0.01
Ppeak (W) 78 ± 21
a 165 ± 60 < 0.05
[L−]rest (mmol L
−1) 1.64 ± 0.88 1.11 ± 0.62 0.207
RER25W (-) 0.72 ± 0.06
a 0.69 ± 0.06 0.447
RERrel (-) 0.78 ± 0.08
a 0.77 ± 0.05 0.923
HRpeak(min
−1) 144 ± 28a 158 ± 16 0.257
tlim (s) 278 ± 154
a 541 ± 321 0.118
MVC (Nm) 54.3 ± 41.9a 80.6 ± 43.3b 0.278
Values are represented as means ± SD. BMC bone mineral content; [L−], blood
lactate concentration at rest; HRpeak peak heart rate, MVC maximum voluntary
contraction, Ppeak peak power; relative V̇O2peak, peak oxygen uptake per kg
body weight; RER25W respiratory exchange ratio at 25 W, RERrel respiratory
exchange ratio at 50 % Ppeak, tlim time to exhaustion.
an = 5; bn = 7
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histological signs of myopathy and/or serum phosphocrea-
tine kinase (CK) elevation, patients featured a history of
muscle weakness, exercise intolerance or exercise-
dependent myalgia (Table 2). Prior to the experiments,
study participants were clinically examined, exclusion cri-
teria were pregnancy as well as cardiac and/or respiratory
disease interfering with exercise tolerance. Several meta-
bolic parameters including plasma lactate, glucose, insulin,
leptin, glycated hemoglobin (HbA1c), thyroid stimulating
hormone (TSH) and CK were measured prio to any study
examination and exercise. Cardiac and respiratory health
were assessed by 24 h - electrocardiogram, cardiac
ultrasound, spirometry and laboratory examination (lipid
profile, glucose, precursorprotein brain natriuretic peptide
(proBNP)). Patients and controls were neither completely
sedentary nor highly active and none of them exhibited
diabetes, coronary heart disease, peripheral vascular
disease or clinically significant hyperlipidemia.
Experimental design
Clinical and physiological assessments were performed.
Clinical assessments consisted of a neurological exam-
ination, muscle strength examination, specific health
questions (SF-36 Health Survey), fatigue severity sub-
scale of the Checklist Individual Strength (CIS-fatigue),
sensation of pain (visual analogue scale, VAS) and a
skeletal muscle biopsy obtained from the vastus latera-
lis muscle. Physiological assessments included a scan
for body composition, an incremental cycling test, a
constant-load cycling test and measurement of knee
extension torque.
Body composition measurement
Total body mass, bone mineral content (BMC), fat mass,
percentage body fat, as well as total lean body mass and
lean soft tissue mass of the leg were determined by
performing dual-energy X-ray absorptiometry (DXA)
measurements using a densitometer (Lunar iDXATM, GE
Healthcare, Madison, WI, USA).
Exercise testing
Each study participant conducted an incremental exer-
cise test on an electrically braked cycle ergometer until
volitional exhaustion (Ergoselect 200 K, Ergoline, Bitz,
Germany) to determine V̇O2peak and Ppeak. Additionally,
all participants performed a constant-load cycling test at
85 % Ppeak to establish time to volitional exhaustion
(tlim). Pulmonary gas exchange and ventilation were
recorded during both exercise tests using an online gas
collection system (Innocor™ M400, Innovision, Odense,
Denmark), where flow, O2 and CO2 concentrations were
recorded breath-by-breath. Flowmeter and gas analysers
were calibrated prior to and after each test according to
the manufacturer’s instructions. Throughout all cycling
tests, heart rate was recorded (Polar S610i, Polar Electro,
Kempele, Finland) and perceived exertion was assessed
via a Borg CR 10 Scale. In addition, blood pressure was
registered on a regular basis during the incremental
cycling test. The incremental cycling test consisted of a
3 min rest phase followed by 2 min at 25 W with power
increments of 25 W every 2 min until volitional ex-
haustion. Pedal cadences were freely chosen by the
participants within a range of 60 and 80 revolutions per
minute (rpm) and had to be remained constant
Table 2 Clinical and molecular characteristics of patients with mitochondrial myopathy
Patient Sex Age of
onset
(yr)
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4 f 12 MM exercise induced myalgia 206 normal mtDNA
deletion 10–
13 kbp
35 % COX−, SDH+,
ragged red
fibers
5 f 20 MM exercise induced myalgia normal normal mtDNA
deletion 6–
10 kbp
62 % ragged red
fibers






[CK], blood creatine kinase concentration at rest; COX− cytochrome oxidase negative fibers, CPEO chronic progressive external ophthalmoplegia, [L−], blood lactate
concentration at rest; MM mitochondrial myopathy, mtDNA mitochondrial DNA, SDH+ succinate dehydrogenase positive fibers
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throughout the test. V̇O2peak was determined as the
highest mean over a 10 s period. The respiratory ex-
change ratios (RER) for submaximal power values were
calculated as the mean of the last 30 s at 25 W (RER25W)
and as the mean over 10 s at 50 % Ppeak (RERrel). The
constant-load cycling test included a 3 min rest phase, a
3 min warm-up with 1 min at 40 % and 2 min at 60 %
Ppeak, and a constant-load phase at 85 % Ppeak until vol-
itional exhaustion.
Isokinetic dynamometry
Knee extensor maximal voluntary contraction torque
(MVC) was assessed using an isokinetic dynamometer
(Con-Trex MJ, Physiomed Elektromedizin, Schnaittach/
Laipersdorf, Germany). Participants’ bodies were stabi-
lised with straps and handles according to the guidelines
of the manufacturer. Each participant performed three
maximal knee extensions (ω = 3.14 rad s−1) separated by
1 min rest to assess MVC, whereby only the highest
value out of the three trials was used for statistical
analysis.
Skeletal muscle sampling
Participants were tested for coagulation abnormalities
(Quick/INR, number of thrombocytes). Skeletal muscle
biopsies were obtained under standardised conditions
from the vastus lateralis muscle under local anesthesia
(1 % lidocaine) of the skin and superficial muscle fascia,
using the Bergström technique with a needle modified
for suction. The biopsy was immediately dissected
macroscopically free of fat and connective tissue and di-
vided into sections for actual measurement of mitochon-
drial respiratory capacity, later transmission electron
microscopy (TEM) and histochemistry. The part of the
biopsy for the determination of mitochondrial respira-
tory capacity was directly placed in ice-cold biopsy pres-
ervation solution. For TEM, pieces of around 1 mm3 of
each muscle biopsy were chemically fixed in 2.5 %
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3),
stored at room temperature (RT) for 24 h and thereafter
at 4 °C until all samples were collected. Muscle tissue
for immunohistochemistry was instantly mounted in an
embedding medium (Tissue-Tek®, Sakura, Zoeterwoude,
The Netherlands), snap frozen in isopentane cooled to
−160 °C with liquid nitrogen, and subsequently stored at
−80 °C until further processing.
Mitochondrial respiration measurement
Samples were prepared as described in detail previously
[24]. Summarised, after mechanical fiber separation,
chemical permeabilization in biopsy preservation solu-
tion and washing in mitochondrial respiration medium
05, muscle bundles were blotted dry and measured for
wet weight (ww) in a balance-controlled scale (XS205
DualRange Analytical Balance, Mettler-Toledo AG, Grei-
fensee, Switzerland). Respiration measurements were
subsequently performed in mitochondrial respiration
medium 06. O2 consumption of the individual muscle
tissue was thereby measured at 37 °C using the high-
resolution Oxygraph-2 k (Oroboros, Innsbruck, Austria).
Standardised instrumental and chemical calibrations
were performed as recommended by the manufacturer
and described previously [24]. O2 flux was automatically
calculated by the software, accounting for nonlinear
changes in the negative time derivative of the O2-
concentration signal (DatLab, Oroboros, Innsbruck,
Austria). Experiments were performed as duplicates in a
hyperoxygenated environment in order to prevent any
potential O2 diffusion limitation. Thereby, O2 concentra-
tion ranged between 200 and 450 nmol mL−1 within the
chambers.
Respiratory titration protocol
The respiratory measurement protocol was specific to
the analysis of individual aspects of respiratory capacity
and coupling control efficiency during several substrate
states induced via separate titrations. All titrations were
added in series as presented, whereby the concentrations
of substrates, uncouplers and inhibitors used were based
on prior experiments [24]. The titration protocol was
modified from previous protocols where they are de-
scribed in detail [24]. In short, leak respiration in ab-
sence of adenylates (LN) was induced with the addition
of octanoyl carnitine (0.2 mM) and malate (2 mM). Spe-
cifically, LN represents the resting O2 consumption of an
unaltered and intact electron transport system (ETS)
free of adenylates. Maximal electron flow through
electron-transferring flavoprotein and maximal fatty acid
oxidative capacity (PETF) was subsequently determined
following the addition of ADP (5 mM). Electron capacity
through complex I (PCI) was then induced following the
additions of pyruvate (5 mM) and glutamate (10 mM).
Maximal oxidative phosphorylation capacity (P) was in-
duced with the addition of succinate (10 mM). P thereby
represents respiration that results from saturating con-
centrations of ADP and substrate supply both for com-
plex I and II. As an internal control for the integrity of
the mitochondrial preparation, the mitochondrial outer
membrane was assessed with the addition of cytochrome
C (10 μM). ATP synthase was then inhibited by the titra-
tion of oligomycin (1 μM), which leads to oligomycin-
induced leak respiration (LOmy). LOmy represents the
corresponding leak state to P. In LOmy the chemiosmotic
gradient is at maximum because of maximal substrate
supply and inhibition of complex V (ATP synthase).
Additionally, O2 flux is at minimum and is representa-
tive of proton leak, slip, cation cycling and overall dys-
coupling. By uncoupling ATP synthase from the electron
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transport chain with the step-wise titration (4 × 0.5 μM)
of the proton ionophore carbonyl cyanide p-(trifluoro-
methoxy) phenylhydrazone (FCCP) phosphorylative re-
straint of electron transport was assessed reaching ETS
capacity (E). In order to inhibit CI and to assess electron
flow specific to complex II (PCII), rotenone (0.5 μM) was
added. PCII is thereby not influenced by the preceding
addition of FCCP, which was verified with separate pro-
tocols in our laboratory. The addition of antimycin A
(2.5 μM) that inhibits complex III allows the determin-
ation and correction of residual O2 consumption (ROX),
which is indicative of non-mitochondrial O2 consump-
tion in the chamber. Finally, respiration measurements
were terminated by simultaneous titration of ascorbate
and TMPD to assess complex IV (COX) activity. Ascor-
bate and TMPD represent redox substrates that donate
electrons directly to COX. Correction of O2 flux for the
side reaction of auto-oxidation was conducted by chem-
ical calibration experiments prior to the measurements.
Finally, mitochondrial leak control ratios (LCR) were
analysed as well. LCR allow the description of mitochon-
drial coupling efficiency, with a theoretical minimum of
0.0, indicating a fully coupled system, to a value of 1.0,
representing a fully uncoupled system [24, 25].
Transmission electron microscopy
The chemically fixed tissue was washed 3 × in 0.1. M
cacodylate buffer and consecutively post-fixed in 1 %
osmiumtetroxid in 0.1. M cacodylate buffer for 2 h at
RT. After 3 x washing with milliQ H2O, samples were
block-stained with uranyl acetate (2 % in milliQ H2O)
overnight at RT. The subsequent graded dehydration
was conducted in a tissue processor (Leica EM TP, Leica
Microsystems, Wetzlar, Germany) according to the fol-
lowing protocol: 10 min 70 % EtOH, 15 min 96 % EtOH,
4 × 30 min 100 % EtOH, 2 × 5 min and 2 × 10 min pro-
pylene oxide, 2 × 1 h 1:1 propylene oxide/Epon, 1 h
100 % Epon, 100 % Epon over night, 3 h Epon. Finally,
samples were embedded in 100 % Epon in a non-
oriented (isotropic) way and Epon was polymerised for
48 h at 60 °C. Ultrathin sections were cut on an ultrami-
crotome (Ultracut E ultramicrotome, Reichert, NY, USA)
with a diamond knife (Diatome, Biel, Switzerland) and
placed on 50 mesh hexagonal cupper grids (Plano
GmbH, Wetzlar, Germany). Specifically, from each block
three ultrathin sections (70 nm) were obtained at two
depths separated by 20 μm and placed onto two grids.
Finally, the grids were contrasted with lead citrate [26].
Micrographs were obtained in a FEI Tecnai G2 Spirit
electron microscope (Tecnai G2 Spirit, FEI, Hillsboro,
OR, USA) mounted with an Orius SC1000 charged-
coupled device camera (Gatan, Pleasanton, GA, USA)
and interfaced with the TEM software (TEM User Inter-
face, FEI, Hillsboro, OR, USA). Micrographs were
acquired in a uniform random systematic order. For
each grid three predetermined positions were marked
for further imaging. At each position an area of 222 ×
146 μm2 (pixel size of 57.7 nm) was used for automated
image capturing by the TEM photomontage software. A
random starting point was selected for the first micro-
graph whereafter further micrographs were taken at
fixed x-, y-intervals of 64 and 42 μm, respectively. Nine
15.9 × 10.5 μm2 micrographs (3840 × 2528 pixels) were
captured in each area. Consequently, for each biopsy a
total of 54 micrographs were acquired (nine micrographs
per three positions per two sections per sample). Subse-
quently, skeletal muscle volume density of mitochondria
(MitoVD) was estimated by point counting in combin-
ation with Cavalieri’s principle [27] using the Stereo-
Investigator software (MBF Bioscience, Williston, ND,
USA). For point counting a grid spacing of 1 μm along
bot x- and y-axis was applied. Each point was assigned
as either intermyofibrilar (IMFVD) or subsarcolemmal
(SSVD) mitochondrial volume density, lipid droplet vol-
ume density (LDVD), skeletal muscle or “nothing”. SS
mitochondria were defined as the mitochondria that
were not separated by myofibrils from the sarcolemma.
Histochemistry
Consecutive transverse sections (8 μm) were cut at three
depths on a microtome (Leica CM 1850, Leica Biosys-
tems, Wetzlar, Germany) at −22 °C, mounted on glass
cover slides (Superfrost Plus, Thermo Fisher Scientific
Inc., Rockford, IL, USA), set to air dry and stored at
-20 °C until further processing. The serial sections were
then fixed in 3 % neutral buffered formalin at RT for
45 min, briefly washed and blocked with 5 % goat serum.
Thereafter, the sections were firstly incubated with a pri-
mary antibody against myosin heavy chain (MyHC) iso-
form I (Novocastra Lyophilized Mouse Monoclonal
Antibody Myosin Heavy Chain (slow), NCL-MHCs,
Leica Biosystems, Wetzlar, Germany) and secondly with
goat anti-rabbit IgG secondary antibody conjugated with
Alexa Fluor 488 (Thermo Fisher Scientific Inc., Rock-
ford, IL, USA). The sarcolemma of the skeletal muscle
fibers were visualised by incubation with a primary anti-
body against laminin (Novocastra Lyophilized Mouse
Monoclonal Antibody Laminin, NCL-LAMININ, Leica
Biosystems, Wetzlar, Germany) in combination with goat
anti-rabbit IgG secondary antibody, Alexa Fluor 647
conjugate (Thermo Fisher Scientific Inc., Rockford, IL,
USA). An automated upright microscope system was
used for digitizing the sections (Leica, DM5500 B, Leica
Microsystems, Wetzlar, Germany). Skeletal muscle fiber
type distribution was determined according to their
MyHC-I and MyHC-II isoforms and classified into type
I and type II fibers. For all analyses, only fibers fully
encircled by adjacent fibers were evaluated using Adobe
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Photoshop Pro CS6 (Adobe Systems Incorporated, San
Jose, CA, USA). Fiber cross-sectional area (CSA) was
determined by encircling the boundaries of the muscle
cells of at least 50 fibers per fiber type. Only fibers with
a circularity higher than 0.7 were considered for analysis
(perfect circle = 1.0).
Statistical analysis
All data are presented as mean ± SD in text and figures.
The statistical analysis was conducted using the software
SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). After veri-
fication of normal distribution of the data, two-tailed
unpaired samples t-tests were conducted to test the null
hypothesis stating no difference between patients with
mitochondrial myopathy and healthy controls. For all
statistical analyses, a value of P < 0.05 was considered
significant. To evaluate the effect sizes of the important
findings Cohen’s d were calculated, whereby d < 0.3 is
considerd a small effect, d > 0.3 and < 0.8 a medium ef-
fect and d > 0.8 a large effect. Spearman’s rank correl-
ation coeffiencts were calculated to determine potential
dependences of several variables. The number of pa-
tients and controls included in each data set are always
indicated and can vary due to inability of cycling above a
power output of 0 W (one case) or technical problems
with the devices (two cases).
Results
All participants completed the skeletal muscle biopsy
procedure and DXA measurement. Except from one pa-
tient who was not able to cycle against a certain resist-
ance (25 W), all participants conducted the incremental
and the constant-load cycling exercise test. Due to tech-
nical reasons, one patient and one control could not
perform the isokinetic dynamometry test. There were no
group differences for age, body composition, resting
blood lactate concentration, tlim and MVC (Table 1).
Exercise performance
Ppeak was 53 % lower (P < 0.05, d = 1.8) in patients with
mitochondrial myopathy. In accordance, V̇O2peak was
45 % lower (P < 0.05, d = 1.8) in mitochondrial myopathy
patients than in healthy controls, with a broad range in
both groups (Table 1). However, RER at the same
absolute and relative power output did not differ be-
tween groups, suggesting similar metabolic regulations
in patients and controls at submaximal work rates.
Additionally, tlim in the constant-load test did not differ
between groups.
Skeletal muscle mitochondrial volume density and
respiratory capacity
Maximal mitochondrial respiration specific to each indi-
vidual mitochondrial complex (mass-specific respiration,
respiration per mg ww) was lower (P < 0.05) in patients
with mitochondrial myopathy vs. healthy controls
(Fig. 1a). In particular, difference in mass-specific re-
spiratory capacity with mitochondrial myopathy
amounted to 50 (PCI, d = 2.3), 46 (PCII, d = 1.8), 45 (P, d
= 2.3), 48 (COX, d = 1.8) and 47 % (ETS, d = 2.0). Con-
sidering the range of P for example, patients show a
markedly lower maximal mitochondrial oxidative cap-
acity (44.10 – 81.94 pmol O2 mg
−1 s−1) than controls
(86.54 – 127.89 pmol O2 mg
−1 s−1; P < 0.01). Addition-
ally, MitoVD was on average 23 % lower (P < 0.05, d =
1.5) in patients, which was related to the lower IMFVD
(Table 3, d = 1.4). Moreover, after normalizing mitochon-
drial respiratory capacity to MitoVD all respiratory states
specific to the five mitochondrial complexes were lower
(P < 0.05, Fig. 1b) in patients (28 (PCI, d = 1.9), 24 (PCII,
d = 1.5), 23 (P, d = 1.8), 28 (COX, d = 1.3) and 24 % (ETS,
d = 1.4)), suggesting quantitative and qualitative alter-
ations in mitochondrial function with mitochondrial my-
opathy. In contrast, LCR did not differ (P = 0.501)
between groups (mitochondrial myopathy 0.42 ± 0.07;
controls 0.44 ± 0.05).
Skeletal muscle fiber type distribution
Mitochondrial myopathy patients demonstrated a higher
(P < 0.001, d = 4.2) ratio of type II to I fibers and a ten-
dency (P = 0.070, d = 1.1) towards lower CSA, indicating
potential skeletal muscle atrophy (Table 3). In accordance
with these results, the distribution of type II fibers in
patients ranged from 60.4 – 69.0 % in contrast to 32.8 –
48.8 % in healthy controls. However, CSA specific to type
I and II fibers did not differ (P = 0.133; P = 0.127) between
patients and controls (Table 3).
Correlations
The mutation load in the 6 patients ranged from 12 to
95 %. There was no relationship between percentage muta-
tion and any of the other determined variables. V̇O2peak
was positively correlated (P < 0.05) to P (ρ = 0.626), MitoVD
(ρ = 0.577) and P normalised to MitoVD (ρ = 0.648). More-
over, P, MitoVD, P/MitoVD as well as lean mass were all
related to CSA of type I fibers (ρ=0.653, ρ=0.600, ρ=0.618,
ρ=0.578; P< 0.05).
Discussion
The main finding of the present study is that skeletal
muscle mitochondrial function in mitochondrial myop-
athy patients is lower than in healthy controls due to
reduced mitochondrial volume density as well as dimin-
ished intrinsic mitochondrial function. Furthermore,
patients exhibited a shift in skeletal muscle fiber type to-
wards more type II fibers and tended to an atrophic
muscle phenotype. Moreover, V̇O2peak and Ppeak in pa-
tients with mitochondrial myopathy were lower than in
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healthy controls. Mitochondrial volume density and
maximal oxidative phosphorylation capacity were posi-
tively correlated to V̇O2peak. Thus, mitochondrial myop-
athy is associated with decreased mitochondrial quantity
and quality as well as diminished capacity for whole-
body maximal O2 uptake.
This study determined skeletal muscle mitochondrial














































































Fig. 1 Mass-specific mitochondrial (a) and mitochondrial-specific (b) respiratory capacity (normalised to MitoVD). Respiratory capacities are presented for
patients with mitochondrial myopathy in white bars and healthy controls in black bars) LN, leak respiration without adenylates; PETF, fatty acid oxidative
capacity; PCI, respiratory capacity of complex I; P, oxidative phosphorylation capacity; LOmy, oligomycin-induced leak respiration; E, electron transport system
capacity; PCII, respiratory capacity of complex II; ROX, residual oxygen consumption; COX, respiratory capacity of complex IV. Values are mean ± SD. *P<
0.05; **P< 0.01. nPatients = 6, nControls = 8
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complex I-V in permeabilised fibers from mitochondrial
myopathy patients in comparison to age- and gender-
matched healthy controls. Thereby, not only MitoVD but
also the mass-specific (per mg ww) and mitochondrial-
specific (normalised to MitoVD) respiratory capacity of
each individual complex were affected by mitochondrial
myopathy, indicating an evident impairment of innate
mitochondrial function. This lower mitochondrial func-
tion may lead to greater disturbances in homeostasis in
skeletal muscle, higher reliance on muscle glycogen,
increased lactate production and, therewith, lower
exercise capacity compared to healthy individuals [28].
Moreover, these alterations could limit the skeletal mus-
cle’s ability to extract and/or oxidize O2 from the blood
[14, 28], potentially resulting in an impaired V̇O2peak.
Particularly, the lower O2 extraction capacity of the
skeletal muscle is likely to lead to a higher systemic O2
delivery relative to O2 utilization, i.e. a hyperkinetic
circulation, causing typical symptoms of mitochondrial
myopathy such as metabolic acidosis, exertional dys-
pnea, exercise intolerance, low exercise performance and
consecutively reduced quality of life [10–13, 29].
Hence, the present bioenergetic impairments at the
cell organelles’ level result in abnormal cardiac and
ventilatory responses to increased O2 requirements as in
response to physical activity and exercise [29–31], and
might impair exercise capacity in patients with mito-
chondrial myopathy. Noteworthy, exercise capacity in
patients with mitochondrial myopathy was lower com-
pared to healthy controls and varied broadly, reflecting
the heterogenous clinical manifestation and severity of
this disease. In addition, V̇O2peak correlated with mea-
sures of mitochondrial quantity and quality, indicating
an association with reduced skeletal muscle O2 uptake
capacity, which has been indicated by previous studies in
our laboratory before [32, 33]. In support, diminished
V̇O2peak may be entirely explained by a lower systemic
a-vO2 diff [10–13], since peak cardiac output (Q̇peak) has
been reported not to differ between mitochondrial
myopathy and healthy controls [11]. Although these
metabolic adaptations in skeletal muscle are critical for
physical activity, especially for submaximal exercise
performance, V̇O2peak is limited by O2 transport capacity
in healthy human individuals whithout metabolic distur-
bances [34–36].
To our knowledge, this is also the first study demon-
strating skeletal muscle fiber type transformation from
type I to type II fibers in adult mitochondrial myopathy
patients. This finding contrasts to the histochemically
described type I fiber predominance as a compensation
for impaired energy production and mitochondrial func-
tion in children with mitochondrial myopathy [8]. As
type I fibers usually contain a higher proportion of mito-
chondria than type II fibers [37], an enhanced ratio of
type I as compared to type II fibers could increase the
number of mitochondria and lead to a potentially greater
capacity for energy production [8]. In turn, decreased
oxidative capacity could also be compensated by a
switch from an oxidative to a more glycolytic phenotype
in order to partially restore muscle strength and energy
production, yet leading to higher lactic acid production,
which is characteristic for this disease [10, 38]. Lactate
in turn represents an important fuel for oxidative metab-
olism and has been reported to rather enhance energy
production than inducing fatigue in patients with mito-
chondrial myopathy [39]. In support of our findings,
Venhoff et al. [9] reported a fiber type shift from type I
to type II fibers in rodent models of mitochondrial my-
opathy. The lower MitoVD in patients with mitochon-
drial myopathy, which was related to lower IMFVD, may
thereby reflect the decreased type I to type II fiber ratio
and the potentially higher reliance on glycogen metabol-
ism. SSVD in the present study did not differ and only
half of the mitochondrial myopathy patients demon-
strated ragged-red fibers (RRF, Table 2). Together these
findings contrast previous reports of SS mitochondrial
proliferations and simulatenously occurring RRF with
mitochondrial myopathy [8, 40, 41]. Moreover, mouse
models of mitochondrial myopathy demonstrated RRF
and increased skeletal muscle mitochondrial volume
density, particularly in the SS region, wheras respiratory
chain enzyme activites were decreased [42]. Therefore,
the authors suggested the higher mitochondrial volume
density to partly compensate for the respiratory chain
deficiency and the redcued mitochondrial ATP produc-
tion being not as critical for the pathophysiology of
mitochondrial myopathy as previously thought [42]. Ac-
cordingly, recent studies displayed altered Ca2+ handling
in mitochondrial myopathy [43, 44], stimulating the
discussion of progressive muscle weakness rather than
Table 3 Skeletal muscle properties of patients with
mitochondrial myopathy (n = 6) and healthy controls (n = 8)
Patients Controls P-value
Type I fibers (%) 34.8 ± 3.6 55.7 ± 5.9 < 0.001
Type II fibers (%) 65.2 ± 3.6 44.3 ± 5.9 < 0.001
CSA total (μm2) 3,438 ± 915 4,698 ± 1,328 0.070
CSA type I fibers (μm2) 3991 ± 1211 5234 ± 1566 0.133
CSA type II fibers (μm2) 3,178 ± 852 4,359 ± 1,592 0.127
MitoVD (%) 4.0 ± 0.5 5.1 ± 0.8 < 0.05
IMFVD (%) 3.4 ± 0.4 4.1 ± 0.5 < 0.05
SSVD (%) 0.6 ± 0.3 1.0 ± 0.5 0.118
LDVD (%) 0.4 ± 0.1 0.4 ± 0.3 0.660
Values are represented as means ± SD. CSA cross sectional area; IMFVD
intermyofibrilar mitochondrial volume density, LDVD lipid droplet volume
density, MitoVD mitochondrial volume density, SSVD subsarcolemmal
mitochondrial volume density
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energy deficiency as the potential dominating pathome-
chanism [44]. Collectively, these partially divergent find-
ings may once more reflect the heterogenous character
of this disease and the possible detrimental effect of
physical inactivity in mitochondrial myopathy patients,
which in turn emphasizes the need for further studies
also on alternate pathophysiological mechanisms.
Discriminating exercise intolerance caused by defective
mitochondria from that of disease-associated inactivity
and hence physical deconditioning remains challenging.
Exercise intolerance inevitably results in reduced levels
of habitual physical activity and causes physical decondi-
tioning, which in turn leads to a vicious cycle of further
deconditioning and progressive exercise intolerance [45].
Similar total lean mass and lean mass of the lower limbs
in mitochondrial myopathy patients and healthy controls
may suggest that the diminished mitochondrial volume
density, as well as the reduced function and exercise per-
formance are possibly associated with the disease itself
rather than with inactivity alone. Moreover, MVC and
tlim did not significantly differ between patients with
mitochondrial myopathy and healthy controls, which
contradicts different levels of physical activity. In sup-
port, mice with mitochondrial myopathy showed a
decrease in ATP levels even with exercise, which was
less than in sedentary diseased mice but dropped to
30 % of wild-type after 10 month [46]. Nonetheless, in
spite of matching patients and controls according to age,
gender and, as far as possible, to reported physical activ-
ity levels, the lower V̇O2peak and Ppeak in patients with
mitochondrial myopathy could be due to sustained phys-
ical inactivity associated with the disease-related exercise
intolerance. Thereby, the present lower MitoVD and
mitochondrial respiratory capacity in patients with mito-
chondrial myopathy could indeed also simply be a reflec-
tion of this vicious cycle. Disuse and physical inactivity,
respectively, have been reported to lead to decreases in
mitochondrial volume density and hence mitochondrial
function [47, 48]. In line herewith is the lower IMFVD
with mitochondrial myopathy, as IMF mitochondria
represent a specialization towards energy production for
contractile activity [49]. Reduced contractile activity due
to physical inactivity in patients with mitochondrial my-
opathy could have resulted in lower IMFVD and second-
ary impaired mitochondrial function. In support, muscle
homogenates of mice with mitochondrial myopathy due
to a COX deficiency exhibited increased mitochondrial
mass, oxidative capacity and exercise performance after
an endurance exercise training intervention in compari-
son to sedentary diseased mice [46]. However, although
the enhanced physical activity led to a preservation of
oxidative capacity of 50 – 60 % of wild-type levels in
comparison to the drop to 10 – 40 % in sedentary
diseased mice in 3 month duration, oxidative capacity
still remained reduced compared to wild-type controls.
Moreover, mitochondrial COX activity was not affected
by the exercise intervention [46]. The oxidative capacity
in muscle homogenates, which was sustained only
partially, together with the persistent COX defect at the
mitochondrial level in exercised diseased mice indicates
increased mitochondrial quantity but not quality with
exercise [46]. Therefore, lower MitoVD but not impaired
intrinsic mitochondrial function could be explained by
physical inactivity secondarily to exercise intolerance.
Congruently, two weeks of physical inactivity induced by
one leg immobilization led to reduced mitochondrial
respiratory capacity due to changes in mitochondrial
content but not intrinsic mitochondrial function [47].
Moreover, considering the shift towards more type II fi-
bers and the trend to general fiber atrophy, physical in-
activity should be considered as a potential cause.
However, muscle disuse affects mainly type I fiber diam-
eter [50, 51], which did not differ between patients and
controls. This is further supported by a rat model of
mitochondrial myopathy harborating a predominate type
II fiber atrophy [9]. Conclusively, mechanisms related to
mitochondrial dysfunction and the disease-causing mu-
tations itself could have induced the present pathologic
findings. However, physical inactivity could secondarily
have led to further aggraviation of decreased exercise
capacity and mitochondrial function. Therefore, the
present study cannot definitively clarify whether the
findings are related to the disease per se or in addition
to inacitivity. Another limitation of the present study is
the small sample size, which hovewer, according to the
preceding power calculation and the significant differ-
ences of the main results was sufficient. The small num-
ber of participants can be explained by the large
expected contrasts in MitoVD and mitochondrial respira-
tory capacity between patients with mitochondrial my-
opathy and healthy controls and the small coefficients of
variation for the TEM and high-resolution respirometry.
The present findings in this small cohort with a rather
inhomogenous degree of heteroplasmy are further
strengthend by the high effect sizes.
From a clinical point of view, the diagnosis of mito-
chondrial cytopathy or mitochondrial myopathy, respect-
ively, remains challenging and requires the combined
application of multiple methodologies [52]. Blood sam-
ples may exhibit increased resting lactate concentrations
and elevated CK levels. However, lactic acidosis is often
not present and CK levels may be normal or only mildly
increased. Functional muscle testing with the subanaero-
bic threshold exercise test (SATET) is a very specific
measure for mitochondrial pathology [53] but many
mitochondrial myopathy patients do not exhibit patho-
logical values. Morphological, biochemical and molecu-
lar studies in tissue samples allow a diagnosis by the
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presence of suggestive histopathological findings such as
RRF and ragged-blue fibers, COX depleted fibers,
variously formed mitochondria, abnormal cristae, crys-
talloid inclusions and the determination of disease-
causing mutations in the mitochondrial and/or nuclear
DNA [41, 52]. As demonstrated in two of our six pa-
tients, these typical histological signs of mitochondrial
myopathy can be lacking despite presence of a mito-
chondrial disease [52]. Molecular genetic analysis of
mitochondrial DNA in tissues may demonstrate hetero-
plasmic deletions and point mutations. In addition, nu-
clear DNA mutations need to be considered. For
heteroplasmic mitochondrial DNA mutations, the de-
gree of heteroplasmy needs to be quantified, but the
pathological threshold is poorly defined, particularly in
mitochondrial cytopathy patients at advanaced age. This
heteroplasmy, a canonical criteria for the pathogenity, is
not always given as also pathogenic homoplasmic muta-
tions have been described [3, 54]. This aspect also causes
some limitations regarding the results of the present
study and their generalization for all mitochondrial
myopathy patients. As we included only patients with
mitochondrial DNA single deletions, the present re-
sults are only true for this spectrum of phenotype
and further investigations considering patients with
mitochondrial DNA point mutations and nuclear
DNA mutations affecting mitochondria are needed to
verify these findings.
To provide proper patient management, treatment
and genetic counseling, a clear diagnosis of mitochon-
drial cytopathies is necessary. Our results demonstrate
that high-resolution respirometry measurements could
represent a promising additional tool for the diagnosis
of mitochondrial cytopathies. In vitro measurements
as the present high-resolution respirometry allow the
estimation of the functionality of specific steps impli-
cated in mitochondrial metabolism by the use of
various substrates, uncouplers and inhibitors. Such
polarographic measurements of O2 consumption pro-
vide more essential information on innate mitochon-
drial function, as evaluations not only of isolated
mitochondria but also of permeabilised cells are pos-
sible [55]. In contrast to the isolation procedure,
permeabilization of muscle fibers preserves mitochon-
drial morphology and integrity and allows the exam-
ination of the intact mitochondrial network [22].
However, the definition of normal ranges of complex
activites in skeletal muscle remains disputed and diffi-
cult. Since a skeletal muscle biopsy is needed for this
approach, this minimal-invasive procedure represents
a disadvantage for the patients. Conclusively, further
studies to eliminate the variations and to validate
high-resolution respirometry as a diagnostic measure
are needed.
Conclusion
Mitochondrial myopathy led to diminished skeletal
muscle mitochondrial volume density and respiratory
capacity of each individual complex and was related to
reduced maximal exercise capacity. Lower mitochondrial
volume density was attended by a shift in skeletal muscle
phenotype from type I to type II fibers, reflecting a pos-
sible compensation for the lower mitochondrial respira-
tory as well as exercise capacity. Hence, the affected
mitochondrial quantity and quality could be responsible
for the impaired exercise capacity and could further ag-
gravate exercise intolerance. However, it cannot be ex-
cluded that changes observed in patients are simply due
to physical inactivity as a cause of the disease-related
exercise intolerance. Nonetheless, the clearly reduced
mitochondrial respiratory capacity in patients with
mitochondrial myopathy compared to age- and gender-
matched healthy controls proposes high-resolution respi-
rometry measurements in permeabilised skeletal muscle
fibers to be a promising additional diagnostic tool.
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